The recommended bone turnover markers (BTMs) for monitoring osteoporosis treatment in postmenopausal populations have traditionally been limited to CTX-I and PINP. IDS has previously advocated for the use of BAP and osteocalcin (OC) as alternatives to PINP, and highlighted the relevance of BAP and TRAcP 5b in chronic kidney disease (CKD) populations.
Abacus dx are pleased to share that a newly published position paper now formally recommends BAP and TRAcP 5b as reference BTMs for CKD-associated osteoporosis. The paper emphasises their inclusion in both observational and interventional studies to evaluate their effectiveness in risk assessment, treatment initiation, and monitoring treatment response in this specific population.
Additionally, the April/May 2025 issue of Clinical Laboratory International (CLI) features an insightful article titled “Bone Turnover Markers for Diagnostics and Therapy Monitoring”, which further explores the evolving role of BTMs in clinical practice.
THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.
